News
Semaglutide Alzheimer's Trial: What EVOKE Found
Two large trials gave people with early Alzheimer's disease a daily semaglutide tablet or a placebo for two years. Decline was the same in both groups. Here is what was measured, what moved, and what is still unanswered.
Read article →-
Sermorelin for Sleep: What the Research Shows
The link between growth hormone and deep sleep is real. The evidence that sermorelin improves sleep is not: the one trial that tested it found slightly worse sleep scores.
-
Tirzepatide Myths: 9 Claims Checked
Nine things people say about tirzepatide, each graded supported, partly, not supported or unknown against the clinical trials and the current label.
-
Who Invented Semaglutide? The Team Behind Ozempic
Semaglutide was not one person's eureka moment. A small Novo Nordisk team spent years turning a hormone that lasts minutes into a medicine that lasts a week. Here are the people, the paper and the patent.
-
Does Tirzepatide Cause Depression? The Evidence
Tirzepatide's own trials, FDA's 2026 class review and large health-record studies have not found that it causes depression or suicidal thoughts. A new low mood still deserves a prompt conversation with the prescriber.
-
Mounjaro Prescribing Information, Explained
The current Mounjaro label is revised August 2026. It added a heart-risk use, stopped calling 2.5 mg a starter-only dose, and reworded an eye warning. Here is the whole document in plain words.
-
SUMMIT Trial Tirzepatide Results in Heart Failure
SUMMIT gave tirzepatide or placebo to 731 adults with obesity and HFpEF, a stiff-heart form of heart failure. Heart-failure flare-ups fell and symptoms improved; deaths did not, and no U.S. label lists heart failure.
-
12 Questions to Ask About Peptide Therapy
Twelve questions worth bringing to a peptide visit, grouped by what they uncover: the evidence, the review status, your own health and the vial itself, with why each is asked and what a straight answer sounds like.
-
Semaglutide Diarrhea: How Common and How Long
Diarrhea is one of semaglutide's most common side effects, especially while the dose is still climbing. Most episodes in the trials lasted about three days; the ones that keep going are the ones to report.
-
SURMOUNT-5 Results: Tirzepatide vs Semaglutide
SURMOUNT-5 put 751 adults without diabetes on tirzepatide or semaglutide for 72 weeks. They lost an average of 20.2% and 13.7% of their body weight, and the comparison has limits worth knowing.
-
Who Discovered GHK-Cu? Loren Pickart, in 1973
Loren Pickart reported the peptide in human serum in 1973, its sequence followed in 1977 and its grip on copper in 1980. The history is well documented; the human evidence is much thinner.
-
PT-141 Clinical Trials: What RECONNECT Found
The pivotal studies found modest improvements in desire and distress in a specific group of premenopausal women. They also found a high nausea rate, a sizable placebo response, and clear limits on what the results can tell us about men or compounded PT-141.
-
10 Questions to Ask Doctor About Semaglutide
A semaglutide intake is a safety conversation, not a quiz. These ten questions show what the provider needs to know and why each answer matters.
-
Does Semaglutide Cause Acid Reflux? Sometimes
Heartburn and indigestion are listed semaglutide side effects, more common than on placebo but far less common than nausea. Here is how often they show up, why, when they peak, and which signs need a doctor.
-
SURMOUNT-OSA Results: What the Trial Found
Two linked trials found 20 to 24 fewer breathing interruptions per hour with tirzepatide than with placebo after 52 weeks. The result was large, but it applies to a specific group: adults with obesity and moderate-to-severe obstructive sleep apnea.
-
Tirzepatide and Caffeine: Is Coffee Okay?
The current Zepbound label does not list caffeine as an interaction. Coffee may still feel different when nausea, a faster heartbeat, fluid loss, or poor sleep is already in the picture.
-
Exercise on Tirzepatide: What the Evidence Shows
Movement was part of the major tirzepatide trials, but they did not test one special workout. The useful evidence is about the trial setting, lean tissue, low blood sugar, and dehydration.
-
Compounded Semaglutide Adverse Events: FDA Update
FDA now lists 990 adverse-event reports associated with compounded semaglutide and more than 730 with compounded tirzepatide. The counts matter, but they are reports rather than proof of cause or a rate of harm.
-
FLOW Trial Semaglutide Results: What 24% Means
FLOW followed 3,533 adults with type 2 diabetes and chronic kidney disease. The headline was a 24% lower risk for a bundle of serious kidney and cardiovascular outcomes, not a promise that kidney disease would disappear.
-
Semaglutide and Intermittent Fasting: What We Know
No published randomized weight-loss trial has shown that intermittent fasting adds a benefit to semaglutide. The safest answer depends on diabetes medicines, side effects, hydration, and whether the eating window leaves enough room for nutrition.
Page 1 of 18 · 344 articles